2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
about
The Relevance of Gynecologic Oncologists to Provide High-Quality of Care to Women with Gynecological CancerSelecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patientsRole of aggressive surgical cytoreduction in advanced ovarian cancerPatient preferences in advanced or recurrent ovarian cancer.Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma.The COMET Handbook: version 1.0.Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.SEOM guideline in ovarian cancer 2014.Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionTrabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancerHyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational studyHormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer.Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary diseaseStandard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.A review of patient and carer participation and the use of qualitative research in the development of core outcome setsPrimary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): Mapping probable mechanisms and targets using systems oncologyOvarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.Update on first-line treatment of advanced ovarian carcinoma.Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancerThe role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancerThe cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada.Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.SEOM Clinical Guideline in ovarian cancer (2016)Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed?Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
P2860
Q26770278-834ECFAD-0BB9-435C-A250-E3F6CBEB4A56Q26771731-409ECBF9-36CB-4580-98EF-C03D0EC5E29BQ26801358-D2A14E3B-03C6-4405-A2E8-D24FE00B2B83Q27336251-483C0D02-31D4-4EC2-9E41-AA96D126B491Q27692699-D162D2A2-71CD-4AF4-B55A-629B7D39674EQ30717971-2FEFAD67-E333-45AA-9A78-B1B823E6D26EQ33644637-5880FE03-9B09-4E52-B0C8-CC7AC2B53A39Q33877196-8EB4D876-4BB5-4F47-A611-2FE9ED14EE0DQ34350701-7FA4C975-F6E7-4723-A3A6-EB111A94CDD1Q34553508-54729C14-1A06-4865-855E-B19A264F044FQ34916073-20E4A28B-C2D0-4B0B-B75E-CE9630728FADQ34996149-689915F9-47D1-4F84-94AE-D2FF22ED89E6Q34996992-3264924E-4033-4231-B1CA-5A2DFD2903FEQ35510378-AD0F3F7F-CEBA-4F3C-8084-C81D90C26C13Q35562702-29131A80-882B-4AD2-B2B8-736026409D97Q35872796-9D79D896-F08F-4459-A135-8E7A94CB2D94Q36063233-DCD289E1-D190-4B0B-9C8D-90753A54E663Q36109709-28356679-E842-46BA-9558-19E75C127600Q36140826-88B39746-9526-4876-866D-7C5A86D16BDDQ36248459-BB993D3E-CAA8-430E-AE83-14F80E4B0D4FQ36287626-0879A9E0-5945-4080-BFE7-4E285E024646Q36310440-69E3196B-5F3F-41A0-BE2B-D7458359CE6CQ36432206-787944C2-ED3F-4D64-A326-B3515DFA5EC1Q36433053-88FADACA-39AC-4EDB-AEF9-69AF2409B2E2Q36571743-1AFC3D92-1466-4974-A5B3-F5069B9BFD43Q36728989-3FCD4CE5-4E7F-40AE-97F4-615C7242C4CDQ36822179-5FDF8833-A8D1-49B0-AC91-298BB17B05A5Q36962482-A36D50CB-908C-4255-AE97-BADDAB0571C6Q37227754-CB279E5A-2409-47AF-A018-743CAEB0FB0CQ37258731-EB85CA4F-B107-40F0-8577-FFF905BAA910Q37367910-E33C20C8-1EA3-4175-96E2-401D87BD273CQ37382527-99961770-F9CC-4511-BBAD-093D5124C300Q37475168-48C4B94A-FC08-43DE-81E2-B894028ADF9AQ37686466-6221B5DF-826E-4C75-B727-DCB6F3A9121CQ37701616-F39D06FE-5DF1-40F5-95D8-3A10A4948F64Q37712356-2FA7879F-93D6-490D-A468-707D7029A3C3Q38081238-178B9084-F7EA-4692-923D-C381C1A7DB63Q38090546-931E156B-3CA0-4D60-93BB-FE6A1025643CQ38137231-FC11E546-E202-4DB1-BEE5-94F6B1E48414Q38198095-E130D446-7AA0-458C-BC7B-E07B1863B553
P2860
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
2010 Gynecologic Cancer InterG ...... n Cancer Consensus Conference.
@en
2010 Gynecologic Cancer InterGroup
@nl
type
label
2010 Gynecologic Cancer InterG ...... n Cancer Consensus Conference.
@en
2010 Gynecologic Cancer InterGroup
@nl
prefLabel
2010 Gynecologic Cancer InterG ...... n Cancer Consensus Conference.
@en
2010 Gynecologic Cancer InterGroup
@nl
P2093
P1476
2010 Gynecologic Cancer InterG ...... n Cancer Consensus Conference.
@en
P2093
Andreas duBois
Christian Marth
Edward Trimble
Gavin C E Stuart
Gynecologic Cancer Intergroup
Henry Kitchener
Jonathan Ledermann
Michael Friedlander
Monica Bacon
Tate Thigpen
P304
P356
10.1097/IGC.0B013E31821B2568
P577
2011-05-01T00:00:00Z